Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic...

Related Keywords

London ,City Of ,United Kingdom ,San Diego ,California ,United States ,San Diego Convention Center ,American ,Julia Wilson ,Lauren Williams ,Lydia Lee ,Obecabtagene Autoleucel ,Claire Roddie ,Susana Noonan ,Consultant Haematologist Senior Clinical Research ,American Society Of Hematology ,Sa Noonan Communications ,Globenewswire Inc ,Drug Administration ,Exchange Commission ,Cancer Institute ,Research Department Of Haematology ,University College London ,Nasdaq ,Annual Meeting ,Associate Professor Haematology ,Honorary Consultant Haematologist ,College London ,Chief Executive Officer ,Biologics License Application ,B Cell Acute Lymphoblastic Leukemia ,Pooled Analysis ,Early Phase ,Investigational Therapies ,Expanding Disease Targets ,Diego Convention Center ,Phasei Study Evaluating ,Multiple Myeloma ,Translational Insights ,Consultant Haematologist ,Senior Clinical Research Fellow ,Long Term Efficacy ,Adult Patients ,Refractoryb Cell Acute Lymphoblastic Leukemia ,Poster Session ,Hallsg H ,Study Demonstrating Robust Cell Processing ,Robust Release Testing ,Reliable Logistics ,Sustainable Patient ,Investor Event ,Manchester Grand Hyatt ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,